ArticleNational journal of maxillofacial surgery
To ponder beyond hype!!!
Article in National journal of maxillofacial surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Iatrogenic cushing's syndrome post intralesional triamcinolone acetonide in oral submucous fibrosis: 2 case reports.BMC oral health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, no treatment strategies for oral submucous fibrosis (OSMF) have been proved to be completely effective, and one of the most accepted medical lines of therapy advised in every stage of OSMF is antioxidants. One of the antioxidant drugs has increasingly earned popularity, which is due to its less expensive market price than other available antioxidants formulations. The presence of copper in its composition questions its ability to be effective in the management of OSMF. Moreover, we would like to emphasize that the presence of copper adds on to the disease burden and antioxidants with copper in its composition should not be advised as an antioxidant of choice for the management of OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.